Long-term effects of depot-medroxyprogesterone acetate on lipoprotein metabolism.
To assess the effects of depot-medroxyprogesterone acetate (DMPA) upon serum lipids and lipoproteins, a comparative study in chronic users and new acceptors was undertaken. Two groups of women of reproductive age were included in the study; group I (n = 8) was formed by new acceptors whereas, group II (n = 14) constituted DMPA users of more than five continuous years (7.0 + 2.1 years). Blood samples were taken on the day of injection and 15, 29, 57 and 92 days after the i.m. administration of 150 mg of DMPA for the measurement of total triglycerides (TG), cholesterol (CHOL) and phospholipids (PHL). In addition, the TG and CHOL content in the very low density (VLDL), low density (LDL) and high density (HDL) lipoprotein fractions obtained by ultracentrifugation were also determined. The results demonstrated a moderate increase in the serum total TG concentrations at the expense of the VLDL fraction in the group of chronic DMPA users. In both groups, the administration of DMPA induced a moderate, though not significant, decrease in total CHOL and HDL-chol, an effect that was noticed at the end of the treatment interval; the serum LDL-chol content remained unchanged. In addition, a decrease in the total serum phospholipids content was noticed after DMPA injection in both groups, which resembled the fluctuations observed in the luteal phase of normal ovulating women. The overall data indicate that acute and/or chronic DMPA administration at the dose currently employed for contraception does not induce major abnormalities in lipoproteins in serum.
Garza-Flores
J
J
Department of Reproductive Biology, National Institute of Nutrition, S. Zubirán, México City, México.
De la Cruz
D L
DL
Valles de Bourges
V
V
Sanchez-Nuncio
R
R
Martinez
M
M
Fuziwara
J L
JL
Pérez-Palacios
G
G
D000328:Adult; D003271:Contraceptive Agents, Female / Q000494:pharmacology*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood / Q000187:drug effects*; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D017258:Medroxyprogesterone Acetate
D003271:Contraceptive Agents, Female; D003692:Delayed-Action Preparations; D008055:Lipids; D008074:Lipoproteins; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone